Celecoxib and Cervical Cancer Relationship: In Vitro and Genetic Analysis

A 13.6 KB Excel file published on figshare in May 2026 by Tongfei Wang. It presents results from a study integrating in vitro experiments, network pharmacology, and Mendelian randomization to investigate the anticancer role of celecoxib against cervical cancer and its immune-related mechanisms.

Use Cases

• Validate drug efficacy hypotheses based on in vitro assay results for proliferation, migration, and invasion.
• Identify potential drug targets and pathways using network pharmacology and enrichment analysis.
• Perform causal inference analysis on drug targets and cancer risk using Mendelian randomization techniques.
• Investigate immune cell mediation effects based on the reported mediation percentage of CD25 on specific T cells.

Strengths

• Integrates three distinct methodological approaches: in vitro assays, network pharmacology, and Mendelian randomization.
• Provides specific quantitative results, including an odds ratio (OR = 0.736) and a mediation percentage (28.458%).
• Published under a CC-BY-4.0 license, allowing for open reuse and redistribution.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (13.6 KB), indicating limited scope and likely summary-level results rather than raw experimental data.

Provenance

Source

figshare

Collection Method

Likely contains summarized results from laboratory experiments and statistical analyses.

Freshness

Last updated 2026-05-19 05:41:45; freshness should be verified.